Status:
RECRUITING
The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients
Lead Sponsor:
The First Affiliated Hospital of University of South China
Conditions:
Cirrhosis
Hepotacellular Carcinoma
Eligibility:
All Genders
18-75 years
Brief Summary
Hepatocellular carcinoma (HCC) is a globally prevalent malignancy. In its characteristic "chronic hepatitis-liver cirrhosis-HCC" progression trilogy, patients with cirrhosis demonstrate a 5-year HCC i...
Detailed Description
Patients with liver cirrhosis and chronic hepatitis were enrolled in this clinical trial. The study was designed to investigate the clinical value of serum AKR1B10 in hepatocellular carcinoma (HCC) ri...
Eligibility Criteria
Inclusion
- Meets diagnostic criteria for liver cirrhosis and chronic hepatitis
- Aged 18-75 years, regardless of gender
- Willing to participate in the study and provides signed informed consent
- Has not participated in other clinical trials within the last 3 months
Exclusion
- Pregnancy or lactation
- Incomplete clinical data, serological or imaging records
- Lost to follow-up prior to reaching the observational endpoints
- Aged \<18 years or \>75 years
- Concurrent severe systemic diseases (e.g., involving cardiovascular, cerebral, pulmonary, renal, or hematopoietic systems)
- Current or recent (within 3 months) participation in other clinical trials
- Diagnosed with hepatocellular carcinoma (HCC)
Key Trial Info
Start Date :
May 16 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2028
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT07147335
Start Date
May 16 2025
End Date
March 31 2028
Last Update
August 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of South China
Hengyang, Hunan, China, 421001